Ask one more question
An opportunity to elevate the patient experience
Sometimes, there is so much happening, I’ll only tell the doctors the worst things or what I think they’ll actually deal with. My brain is overloaded knowing I have only a few minutes.”
—Patient living with axSpA
Consultations provide a welcome opportunity for patients to talk about progress, raise any concerns and share their ambitions with their doctor.1 However, some patients struggle to communicate the realities of their condition.
Two-thirds of patients with PsA wish they had more communication with their rheumatologist regarding their disease and their treatment goals.*2
One-third of patients with axSpA say they’ve never discussed treatment goals with their doctor.**3
Asking one more question about what still bothers your patients could uncover new insights that provide a better understanding of their challenges and ultimately, help improve patient outcomes.4
When you have a rheumatologist who talks you through the options and really pays attention, then you feel ready to share.”
—Patient living with PsA
In a recent study exploring patient perspective on HCP practices in axSpA, patients advised:
“Provide patients with adequate time for them to give a complete picture of their experience with their illness, listen to them, believe them, and partner with them”. †5
By pledging to ask one more question, you are showing your support to help patients open up about the true impact PsA and axSpA is having on their lives.
Help uncover the hidden impact of PsA and axSpA
Abbreviations
axSpA, axial spondyloarthritis; EMAS, European Map of Axial Spondyloarthritis; HCP, healthcare professional; PsA, psoriatic arthritis.
Footnotes
*63% of patients with PsA (n=960) “strongly” or “somewhat” agreed with the statement: “I wish my rheumatologist and I talked more about my PsA and treatment goals”. Results from a Harris Poll online patient survey conducted in Australia, Brazil, Canada, France, Spain, Taiwan, UK and USA. Percentages were calculated based on the weighted population as the denominator.2
**One-third of participants stated that they had not talked to their clinician about their personal treatment goals; results from the European Map of Axial Spondyloarthritis (EMAS) involving a cross-sectional survey of individuals with axSpA (n=2846).3
†Exploratory qualitative research study carried out in the US, including 26 adult patients with axSpA.5
References
1. Goold S, Lipkin M. J Gen Intern Med. 1999;14(Suppl 1):S26–S33. 2. Lim I, et al. Rheumatol Ther. 2021;8:761–774. 3. Garrido-Cumbrera M, et al. Curr Rheumatol Rep. 2019;21:19. 4. Georgopoulou S, et al. Rheumatol Int. 2018;38(5):763–775. 5. Lapane KL, et al. BMC Fam Pract. 2021;22:251.
GL-N-DA-RH-2200023
Date of preparation: May 2022
© UCB Biopharma SRL, 2022. All rights reserved.
Intended for healthcare professionals